Name: platelet-rich plasma lysate for treatment of eye surface diseases
Uploaded: 2022-08-02T14:00:00
Description: Watch this Scientific Journal Video about Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases at JoVE.com

作者希望感谢“Casa del Dono di Reggio Emilia”提供供体来源的血小板浓缩物。

用于生长因子定量评估的PRP-L是在AUSL-IRCCS di Reggio Emilia进行的关于再生目的PRP产品表征的更广泛研究中收集的，并于2019年1月10日由Vasta Emilia Nord地区伦理委员会批准（协议号2019 / 0003319）。捐助者根据《赫尔辛基宣言》表示知情同意。收集眼表疾病指数（OSDI）问卷的汇总匿名数据不需要伦理批准，临床医生常规使用该问卷来监测干眼综合征症状。图 1A 显示了所遵循的协议的?...

<ol>
	<li>Everts, P. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Platelet-rich+plasma+and+platelet+gel:+A+review.">Platelet-rich plasma and platelet gel: A review.</a> The Journal of Extra-Corporeal Technology. 38 (2), 174 (2006).</li><li>Giannaccare, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blood+derived+eye+drops+for+the+treatment+of+cornea+and+ocular+surface+diseases.">Blood derived eye drops for the treatment of cornea and ocular surface diseases.</a> Transfusion and Apheresis Science. 56 (4), 595-604 (2017).</li><li>Bernabei, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blood-based+treatments+for+severe+dry+eye+disease:+The+need+of+a+consensus.">Blood-based treatments for severe dry eye disease: The need of a consensus.</a> Journal of Clinical Medicine. 8 (9), 1478 (2019).</li><li>Findlay, Q., Reid, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dry+eye+disease:+When+to+treat+and+when+to+refer.">Dry eye disease: When to treat and when to refer.</a> Australian Prescriber. 41 (5), 160-163 (2018).</li><li>Clayton, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dry+eye.">Dry eye.</a> New England Journal of Medicine. 378 (23), 2212-2223 (2018).</li><li>Jones, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TFOS+DEWS+II+management+and+therapy+report.">TFOS DEWS II management and therapy report.</a> The Ocular Surface. 15 (3), 575-628 (2017).</li><li>Holland, E. J., Darvish, M., Nichols, K. K., Jones, L., Karpecki, P. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Efficacy+of+topical+ophthalmic+drugs+in+the+treatment+of+dry+eye+disease:+A+systematic+literature+review.">Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review.</a> The Ocular Surface. 17 (3), 412-423 (2019).</li><li>Shih, K. C., Lun, C. N., Jhanji, V., Thong, B. Y. H., Tong, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Systematic+review+of+randomized+controlled+trials+in+the+treatment+of+dry+eye+disease+in+Sjogren+syndrome.">Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome.</a> Journal of Inflammation. 14, 26 (2017).</li><li>Rusciano, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Age-related+dry+eye+lactoferrin+and+lactobionic+acid.">Age-related dry eye lactoferrin and lactobionic acid.</a> Ophthalmic Research. 60 (2), 94-99 (2018).</li><li>Craig, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TFOS+DEWS+II+definition+and+classification+report.">TFOS DEWS II definition and classification report.</a> The Ocular Surface. 15 (3), 276-283 (2017).</li><li>Drew, V. J., Tseng, C. L., Seghatchian, J., Burnouf, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reflections+on+dry+eye+syndrome+treatment:+Therapeutic+role+of+blood+products.">Reflections on dry eye syndrome treatment: Therapeutic role of blood products.</a> Frontiers in Medicine. 5, 33 (2018).</li><li>Giannaccare, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blood+derived+eye+drops+for+the+treatment+of+cornea+and+ocular+surface+diseases.">Blood derived eye drops for the treatment of cornea and ocular surface diseases.</a> Transfusion and Apheresis Science. 56 (4), 595-604 (2017).</li><li>Acebes-Huerta, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Platelet-derived+bio-products:+Classification+update,+applications,+concerns+and+new+perspectives.">Platelet-derived bio-products: Classification update, applications, concerns and new perspectives.</a> Transfusion and Apheresis Science. 59 (1), 102716 (2020).</li><li>Quartieri, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Metabolomics+comparison+of+cord+and+peripheral+blood-derived+serum+eye+drops+for+the+treatment+of+dry+eye+disease.">Metabolomics comparison of cord and peripheral blood-derived serum eye drops for the treatment of dry eye disease.</a> Transfusion and Apheresis Science. 60 (4), 103155 (2021).</li><li>Badami, K. G., McKellar, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Allogeneic+serum+eye+drops:+Time+these+became+the+norm.">Allogeneic serum eye drops: Time these became the norm.</a> British Journal of Ophthalmology. 96 (8), 1151-1152 (2012).</li><li>Hwang, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparison+of+clinical+efficacies+of+autologous+serum+eye+drops+in+patients+with+primary+and+secondary+Sj&#246;gren+syndrome.">Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sj&#246;gren syndrome.</a> Cornea. 33 (7), 663-667 (2014).</li><li>Chiang, C. C., Lin, J. M., Chen, W. L., Tsai, Y. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Allogeneic+serum+eye+drops+for+the+treatment+of+severe+dry+eye+in+patients+with+chronic+graft-versus-host+disease.">Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.</a> Cornea. 26 (7), 861-863 (2007).</li><li>Jonsdottir-Buch, S. M., Lieder, R., Sigurjonsson, O. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Platelet+lysates+produced+from+expired+platelet+concentrates+support+growth+and+osteogenic+differentiation+of+mesenchymal+stem+cells.">Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells.</a> PLoS One. 8 (7), 68984 (2013).</li><li>Altaie, A., Owston, H., Jones, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+platelet+lysate+for+bone+regeneration+-+Are+we+ready+for+clinical+translation.">Use of platelet lysate for bone regeneration - Are we ready for clinical translation.</a> World Journal of Stem Cells. 8 (2), 47-55 (2016).</li><li>Vesaluoma, M., Teppo, A. M., Gr&#246;nhagen-Riska, C., Tervo, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Platelet-derived+growth+factor-BB+(PDGF-BB)+in+tear+fluid:+A+potential+modulator+of+corneal+wound+healing+following+photorefractive+keratectomy.">Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: A potential modulator of corneal wound healing following photorefractive keratectomy.</a> Current Eye Research. 16 (8), 825-831 (1997).</li><li>Zheng, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+the+transforming+growth+factor+&#946;+activity+in+normal+and+dry+eye+human+tears+by+CCL-185+cell+bioassay.">Evaluation of the transforming growth factor &#946; activity in normal and dry eye human tears by CCL-185 cell bioassay.</a> Cornea. 29 (9), 1048 (2010).</li><li>Zamani, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Novel+therapeutic+approaches+in+utilizing+platelet+lysate+in+regenerative+medicine:+Are+we+ready+for+clinical+use.">Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use.</a> Journal of Cellular Physiology. 234 (10), 17172-17186 (2019).</li><li>Ministro della Salute. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disposizioni+relative+ai+requisiti+di+qualit&#224;+e+sicurezza+del+sangue+e+degli+emocomponenti.">Disposizioni relative ai requisiti di qualit&#224; e sicurezza del sangue e degli emocomponenti.</a> Italian Ministry of Health. , (2015).</li><li>Aprili, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Raccomandazioni+SIMTI+sugli+emocomponenti+per+uso+non+trasfusionale.">Raccomandazioni SIMTI sugli emocomponenti per uso non trasfusionale.</a> Societ&#224; Italiana di Medicina Trasfusionale e Immunoematologia. , (2012).</li><li>Schiroli, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparison+of+two+alternative+procedures+to+obtain+packed+red+blood+cells+for+&#946;-thalassemia+major+transfusion+therapy.">Comparison of two alternative procedures to obtain packed red blood cells for &#946;-thalassemia major transfusion therapy.</a> Biomolecules. 11 (11), 1638 (2021).</li><li>Pulcini, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Apheresis+platelet+rich-plasma+for+regenerative+medicine:+An+in+vitro+study+on+osteogenic+potential.">Apheresis platelet rich-plasma for regenerative medicine: An in vitro study on osteogenic potential.</a> International Journal of Molecular Science. 22 (16), 8764 (2021).</li><li>Ohashi, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Presence+of+epidermal+growth+factor+in+human+tears.">Presence of epidermal growth factor in human tears.</a> Investigative Ophthalmology &amp; Visual Science. 30 (8), 1879-1882 (1989).</li><li>Vitale, S., Goodman, L. A., Reed, G. F., Smith, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparison+of+the+NEI-VFQ+and+OSDI+questionnaires+in+patients+with+Sj&#246;gren's+syndrome-related+dry+eye.">Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sj&#246;gren's syndrome-related dry eye.</a> Health Quality of Life Outcomes. 2, 44 (2004).</li><li>Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D., Reis, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reliability+and+validity+of+the+Ocular+Surface+Disease+Index.">Reliability and validity of the Ocular Surface Disease Index.</a> Archives of Ophthalmology. 118 (5), 615-621 (2000).</li><li>Zhang, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characteristics+of+platelet+lysate+compared+to+autologous+and+allogeneic+serum+eye+drops.">Characteristics of platelet lysate compared to autologous and allogeneic serum eye drops.</a> Translational Vision Science and Technology. 9 (4), 24 (2020).</li><li>Henschler, R., Gabriel, C., Schallmoser, K., Burnouf, T., Koh, M. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+platelet+lysate+current+standards+and+future+developments.">Human platelet lysate current standards and future developments.</a> Transfusion. 59 (4), 1407-1413 (2019).</li><li>Samarkanova, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Clinical+evaluation+of+allogeneic+eye+drops+from+cord+blood+platelet+lysate.">Clinical evaluation of allogeneic eye drops from cord blood platelet lysate.</a> Blood Transfusion. 19 (4), 347-356 (2021).</li><li>Strunk, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=International+Forum+on+GMP-grade+human+platelet+lysate+for+cell+propagation:+Summary.">International Forum on GMP-grade human platelet lysate for cell propagation: Summary.</a> Vox Sanguinis. 113 (1), 80-87 (2018).</li><li>Schiroli, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+impact+of+COVID-19+outbreak+on+the+Transfusion+Medicine+Unit+of+a+Northern+Italy+Hospital+and+Cancer+Centre.">The impact of COVID-19 outbreak on the Transfusion Medicine Unit of a Northern Italy Hospital and Cancer Centre.</a> Vox Sanguinis. 117 (2), 235-242 (2021).</li><li>Klatte-Schulz, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparative+analysis+of+different+platelet+lysates+and+platelet+rich+preparations+to+stimulate+tendon+cell+biology:+An+in+vitro+study.">Comparative analysis of different platelet lysates and platelet rich preparations to stimulate tendon cell biology: An in vitro study.</a> International Journal of Molecular Science. 19 (1), 212 (2018).</li><li>Fea, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effect+of+autologous+platelet+lysate+eye+drops:+An+in+vivo+confocal+microscopy+study.">The effect of autologous platelet lysate eye drops: An in vivo confocal microscopy study.</a> BioMed Research International. 2016, 8406832 (2016).</li><li>Abu-Ameerh, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Platelet+lysate+promotes+re-epithelialization+of+persistent+epithelial+defects:+A+pilot+study.">Platelet lysate promotes re-epithelialization of persistent epithelial defects: A pilot study.</a> International Ophthalmology. 39 (7), 1483-1490 (2019).</li><li>Geremicca, W., Fonte, C., Vecchio, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blood+components+for+topical+use+in+tissue+regeneration:+evaluation+of+corneal+lesions+treated+with+platelet+lysate+and+considerations+on+repair+mechanisms.">Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms.</a> Blood Transfusion. 8 (2), 107-112 (2010).</li><li>De Paiva, C. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disruption+of+TGF-&#946;+signaling+improves+ocular+surface+epithelial+disease+in+experimental+autoimmune+keratoconjunctivitis+sicca.">Disruption of TGF-&#946; signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca.</a> PLoS One. 6 (12), 29017 (2011).</li></ol>

近年来，基于血小板的产品用于眼表病变的临床使用有所增加，但由于缺乏科学稳健性，它们的扩散受到阻碍。这主要是由于供体来源和制备方案存在很大差异，而供体来源和制备方案通常没有完全披露或不是专门为分配目的而设计的。特别是，仍然缺乏有关通过单采术收集的基于血小板的产品的信息。因此，本工作的目的是描述通过单采术获得的富血小板血浆裂解物（PRP-L）用于治疗DED的逐步?...

血液衍生产品广泛用于伤口护理1、颌面和骨科手术，以及治疗不同的眼表疾病2，如干眼病（DED）3。在DED中，泪膜稳态由于泪液产生和眼表完整性所涉及的不同因素的异常功能而受损4，5。
DED的特征是病因和严重程度6，7，8的异质性，可能是不同因素的结果，如衰老，性别9，隐形眼镜，局部或全身药物10，或干燥综合征10等预先存在的疾病。尽管症状轻微，但DED影响了全世界数百万人，影响了他们的生活质量和卫生系统6。
已经报道了许多针对这种病理的治疗方法，但对于最有效的解决方案仍未达成共识12。迄今为止，人工泪液是旨在恢复泪膜水成分的第一线治疗，尽管这些替代品不含天然泪液的主要生物活性溶质6，11。基于血小板的产品被认为是人工泪液的有效替代品12，13，尽管它们的临床疗效，使用建议和制备方法仍然是一个有争议的问题3。
血液产品在代谢物14、蛋白质、脂质、维生素、离子、生长因子（GFs）、抗氧化化合物11和渗透压（300 mOsm/L）11方面与泪液具有相似的成分。通过其组分的协同活性，它们促进角膜上皮的再生，抑制炎性细胞因子的释放，并增加杯状细胞的数量和结膜中粘蛋白的表达2，3。
到目前为止，文献中已经记录了眼科血液制品的异质性;这些产品可以根据献血者的来源（即自体或同种异体）以及血液来源（即外周血、脐带血、血清或血小板）进行分类。
尽管自体产品是最普遍的3，但同种异体产品现在已成为首选，因为它们确保了更高的功效和安全性标准15，同时显着降低了成本16，17。事实上，先前的研究证明，从自身免疫和/或全身性疾病患者获得的血液产品可能会显示出改变的质量和功能6，16，17。尽管基于血清的滴眼液是最普遍的，但基于血小板的产品最近被确认为一种有效的替代品，因为它们可以很容易地制备，同时保持显着的功效水平3，11。目前可用的基于血小板的产品可分为富血小板血浆（PRP），富血小板血浆裂解物（PRP-L）和富含生长因子的血浆（PRGF）3。
其中，PRP-L具有长寿命冷冻产品的优点。PRP-L可以由单采术，血沉棕黄层甚至过期血小板（PLT）制备18，19，从而大大减少其浪费。等分试样可以在-80°C的输血中心储存数月，甚至可以在-15°C的患者家中储存较短的时间。
PRP-L富含GFs，已被证明可以刺激眼表再生12，20，21。然而，该领域只有很少的临床研究报道，并且所有研究都使用自体来源3，22。PRP-L在常规用于治疗眼表疾病之前仍需要进一步的验证和表征，因为没有关于其制备，分配和储存的标准化指南3。
在此，分享了一个详细的方案，用于生产在意大利雷焦艾米利亚的AUSL-IRCCS输血医学部门使用的PRP-L，并向DED患者分配。我们的目标是帮助科学界开发标准的制备方法，这可能会提高全球研究和临床方法的同质性和一致性。

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Equipments</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>CompoSeal Mobilea II</td>
			<td>Fresenius Kabi, Germany</td>
			<td></td>
			<td>bag sealer</td>
		</tr>
		<tr>
			<td>HeraSafe hood</td>
			<td>Heraeus Instruments, Germany</td>
			<td></td>
			<td>Class II biohazard hood</td>
		</tr>
		<tr>
			<td>MCS+ 9000 Mobile Platelet Collection System</td>
			<td>Haemonetics, Italy</td>
			<td></td>
			<td>automated plasma and multicomponent collection equipment for donating platelet, red cell, plasma, or combination blood components</td>
		</tr>
		<tr>
			<td>Platelet shaker, PF396i</td>
			<td>Helmer, USA</td>
			<td></td>
			<td>Platelet shaker</td>
		</tr>
		<tr>
			<td>Raycell X-ray Blood Irradiator</td>
			<td>MDS Nordion, Canada</td>
			<td></td>
			<td>X-ray Blood Irradiator</td>
		</tr>
		<tr>
			<td>ROTIXA 50RS</td>
			<td>Hettich Zentrifugen, Germany</td>
			<td></td>
			<td>High speed entrifuge</td>
		</tr>
		<tr>
			<td>Sysmex XS-1000i</td>
			<td>Sysmex Europe GMBH, Germany</td>
			<td></td>
			<td>haemocytometer for platelet count</td>
		</tr>
		<tr>
			<td>Warm bath, WB-M15</td>
			<td>Falc Instruments, Italy</td>
			<td></td>
			<td>Warm bath</td>
		</tr>
		<tr>
			<td>Materials</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>ACD-A anticoagulant solution A</td>
			<td>Fenwal Inc., USA</td>
			<td>DIN 00788139</td>
			<td>anticoagulant solution for platelet apheresis (1000 ml)</td>
		</tr>
		<tr>
			<td>BD BACTEC Peds Plus/F Culture vials</td>
			<td>BD Biosciences, USA</td>
			<td>BD 442020</td>
			<td>Sterility assay</td>
		</tr>
		<tr>
			<td>BD BACTEC Peds Plus/F Culture vials</td>
			<td>BD Biosciences, USA</td>
			<td>442020</td>
			<td>At least 2 vials for sterility assay</td>
		</tr>
		<tr>
			<td>BD Luer Lok Syringe</td>
			<td>BD Plastipack, USA</td>
			<td>300865</td>
			<td>At least 4 sterile syringes (50 ml)</td>
		</tr>
		<tr>
			<td>Bio-Plex Human Cancer Panel 1</td>
			<td>BioRad Laboratories, USA</td>
			<td>171AC500M</td>
			<td>Standard panel for PDGF isoforms assessment</td>
		</tr>
		<tr>
			<td>Bio-Plex Human Cancer Panel 2</td>
			<td>BioRad Laboratories, USA</td>
			<td>171AC600M</td>
			<td>Standard panel for EGF assessment</td>
		</tr>
		<tr>
			<td>Bio-Plex MAGPIX Multiplex Reader</td>
			<td>BioRad Laboratories, USA</td>
			<td>Magpix</td>
			<td>This instrument allows multiple immunoassays using functionalized magnetic beads.</td>
		</tr>
		<tr>
			<td>Bio-Plex Pro TGF-b Assay</td>
			<td>BioRad Laboratories, USA</td>
			<td>10024984</td>
			<td>Set and standards for TGFb isoforms assessment</td>
		</tr>
		<tr>
			<td>BioRet</td>
			<td>ARIES s.r.l., Italy</td>
			<td>A2DH0020</td>
			<td>At least 4 piercing spike for blood bags</td>
		</tr>
		<tr>
			<td>Blood collection tube</td>
			<td>BD Vacutainer, USA</td>
			<td>367835</td>
			<td>1 tube, necessary to perform platelet counts</td>
		</tr>
		<tr>
			<td>Eye drops kit. COL Medical Device for the application and preservation of eye drops from haemocomponents</td>
			<td>Biomed Device s.r.l., Italy</td>
			<td>COLC50</td>
			<td>Eye drops kit. At least 2 kits for each PRP unit collected</td>
		</tr>
		<tr>
			<td>Human Cancer PDGF-AB/BB Set 1x96well</td>
			<td>BioRad Laboratories, USA</td>
			<td>171BC511</td>
			<td>Set for PDGF isoforms assessment</td>
		</tr>
		<tr>
			<td>Human Cancer2 EGF Set 1x96well</td>
			<td>BioRad Laboratories, USA</td>
			<td>171BC603M</td>
			<td>Set for EGF assessment</td>
		</tr>
		<tr>
			<td>NaCl 0.9% sterile solution</td>
			<td>Baxter S.p.A., Italy</td>
			<td>B05BB01</td>
			<td>1000 ml</td>
		</tr>
		<tr>
			<td>OSDI Questionnaire</td>
			<td>Allergan Inc., USA</td>
			<td>OSDI</td>
			<td>Ocular Surface Disease Index Questionnaire</td>
		</tr>
		<tr>
			<td>Piercing spike</td>
			<td>BioRet ARIES s.r.l., Italy</td>
			<td>BS051004</td>
			<td>Spike</td>
		</tr>
		<tr>
			<td>Platelet Additive Solution A+ T-PAS+</td>
			<td>TERUMO BCT Inc., Italy</td>
			<td>40842</td>
			<td>preservative solution for platelet concentrates (1000 ml)</td>
		</tr>
		<tr>
			<td>Software Excel</td>
			<td>Microsoft, USA</td>
			<td>Excel</td>
			<td>Data analysis software</td>
		</tr>
		<tr>
			<td>Teruflex Transfer bag 1000 ml</td>
			<td>TERUMO BCT Inc., Italy</td>
			<td>BB*T100BM</td>
			<td>1 for PRP dilution</td>
		</tr>
		<tr>
			<td>Teruflex Transfer bag 300 ml</td>
			<td>TERUMO BCT Inc., Italy</td>
			<td>BB*030CM</td>
			<td>At least 6 for each PRP unit collected</td>
		</tr>
	</tbody>
</table>

platelet-rich plasma lysate for treatment of eye surface diseases

各种眼表疾病用血液来源的眼药水治疗。它们的使用已被引入临床实践，因为它们的代谢物和生长因子含量，可促进眼表再生。血液滴眼液可以由不同的来源（即全血或血小板单采捐献）以及不同的方案（例如，不同的稀释液和冻融循环）制备。这种可变性阻碍了临床方案的标准化，从而阻碍了对其临床疗效的评估。详细说明和分享方法程序可能有助于确定共同准则。在过去的几年中，同种异体产品作为自体治疗的替代品一直在扩散，因为它们保证了更高的疗效标准;其中，富血小板血浆裂解物（PRP-L）滴眼液是通过简单的制造程序制备的。在意大利雷焦艾米利亚的AUSL-IRCCS的输血医学部门，PRP-L是通过血小板单采捐赠获得的。本品最初在0.9%NaCl中稀释至0.3 x 10 9血小板/mL（从平均浓度1 x 109血小板/mL开始）。稀释的血小板被冷冻/解冻，然后离心以消除碎片。将最终体积分成 1.45 mL 等分试样并储存在 −80 °C。 在分配给患者之前，对眼药水进行无菌测试。患者可将血小板裂解物在-15°C下储存长达1个月。生长因子组成也从随机选择的等分试样中评估，并在此处报告平均值。

使用血清源性滴眼液（这是最常用于治疗眼表面疾病的血液产品）的基本原理在于其GF的含量，GF几乎完全来自循环血小板。与外周血血清相比，PRP 含有的血小板数量（因此也含有血小板来源的 GF），范围在 0.15 x 10 9-0.45 x 109 PLT/mL 之间。根据意大利法律，以PRP为单位的血小板计数应至少为0.9 x 10 9-1 x 109 PLT/mL。因此，为了获得模拟血清滴眼液功效的产品，应在裂解?...

Watch this Scientific Journal Video about Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases at JoVE.com

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

血小板裂解物是治疗眼表疾病的新兴工具。在这里，我们提出了一种从血小板供体收集的血小板裂解物的制备，分配，储存和表征的方法。

富血小板血浆裂解物用于治疗眼表疾病

Various ocular surface diseases are treated with blood-derived eye drops. Their use has been introduced in clinical practice because of their metabolite ...

PRP裂解物是一种新兴的血小板产品，用于治疗眼表疾病。在这里，我们想分享和详细说明我们的生产协议，以涵盖通用方法指南的开发。致晕产品作为自体治疗的替代品一直在扩散。因为它们保证了更高的功效标准。PRP裂解物含有高浓度的生长因子。它的生产价格低廉且简单，可以长期储存。使用血液制品治疗眼睛或面部疾病在文献中有大量记载。然而，他们的申请仍未达成共识。原因之一是用于其生产的方法的可变性。我们的目标是分享我们的协议，以开发通用方法。首先，使用通过穿刺尖峰从主袋收集的样本使用血囊计进行血小板计数。用适量的无菌0.9%氯化钠稀释富含血小板的血浆。将稀释的富血小板血浆分成300毫升空收集袋中，达到每袋190毫升的净体积。使用等分试样残留稀释的富血小板血浆进行质量控制，评估可能的微生物污染。按照制造商的说明准备无菌测定，以便在微生物实验室进行测试。在解冻前，将稀释的富含血小板的血浆袋储存在零下 80 摄氏度最多两个月。确保将温水浴设置为37摄氏度。将富含血小板的血浆袋放入温水浴中，等待完全解冻。在室温下以3000倍G离心富含血小板的血浆袋30分钟。利用转移袋的刺穿尖刺，将离心袋与空的无菌 300 毫升转移袋连接。小心地转移PRP裂解物上清液，同时避免碎屑进入新袋中。用袋封口机密封PRP裂解液装置的连接管。用无菌注射器收集 30 至 60 毫升 PRP 裂解液，并将注射器连接到灌装线上的鲁尔锁连接。根据制造商的说明，将旋塞阀旋转半圈，以打开含有注射器和预连接注射器之间的 PRP 裂解液之间的线。用PRP裂解物填充预连接的注射器。断开PRP裂解液注射器。关闭鲁尔锁连接的管盖并将旋塞阀旋转到原始位置。使用滴眼液试剂盒注射器用PRP裂解物填充小瓶。确保每个涂抹器都已正确填充。然后用袋子封口机单独密封它们。使用新的眼药水套件重复该过程。使用少量残留稀释的PRP裂解液来评估可能的微生物污染。正确标记每个涂抹器并将它们放入塑料袋中。也给塑料袋贴上标签。注意突出捐赠者的血型。根据意大利法律和指南，在患者分配之前，在零下 80 摄氏度下储存最多 24 个月。对来自两个不同供体的PRP裂解物中的表皮生长因子，血小板衍生生长因子和转化生长因子β亚型的定量评估表明，每毫升稀释0.3乘以10至第九个血小板的结果与泪液组成最相似。使用PRP裂解物治疗六个月后，眼表疾病指数评分从56加负21下降到45加负21。表明患者生活质量的改善。制备同种异体PRP裂解物的不同方法之间的差异并未证明对在其他组织上测试的PRP裂解物的再生能力有害。需要小心用氯化钠稀释血浆和储存富含血小板的血浆。因为这可能会改变PRP裂解物的组成。比较分析对于调查这些步骤的变化是必要的。

Research

JoVE Journal

Medicine

High Content Screening in Neurodegenerative Diseases

在神经退行性疾病的高内涵筛选

The functional annotation of genomes, construction of molecular networks and novel drug target identification, are important challenges that need to be ...

科研

医学

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

定量自体荧光眼底视网膜疾病的评价

The retinal pigment epithelium (RPE) is juxtaposed to the overlying sensory retina, and supports the function of the visual system. Among the tasks ...

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

在耐药性颞叶癫痫患者卵圆孔电极记录的网络分析

Approximately 30% of epilepsy patients are refractory to antiepileptic drugs. In these cases, surgery is the only alternative to eliminate/control ...

Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

同种异体富血小板血浆 (PRP) 对大鼠分段腱愈合过程的影响: 方法学描述

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a ...

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

富血小板血浆注射液治疗膝关节骨关节炎的制备、程序及评价

Knee osteoarthritis (KOA) is one of the most frequently encountered diseases in the orthopedic department. Existing non-surgical treatments have a limited ...

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

梅博米安腺体功能障碍治疗干眼症的强脉冲光

Dry eye disease (DED) is an increasingly common condition and one of the most common complaints of patients. The vast majority of DED is caused by the ...

Customizing a Cryolite Glass Prosthetic Eye

定制低温玻璃假眼

In Germany, Austria, and Switzerland, over 90% of ocularists still manufacture customized prostheses using cryolite glass from Thuringia. The present ...

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

罗登斯缺血性视网膜疾病的氧诱导视网膜病变模型

One of the commonly used models for ischemic retinopathies is the oxygen-induced retinopathy (OIR) model. Here we describe detailed protocols for the OIR ...

Basophil Activation Test for Allergy Diagnosis

嗜碱性粒细胞活化试验用于过敏诊断

The basophil activation test (BAT) is a complementary in vitro diagnostic test that can be used in addition to clinical history, skin test (ST), and ...

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

非人灵长类动物模型中视网膜色素上皮移植治疗退行性视网膜疾病

Retinal pigment epithelial (RPE) transplantation holds great promise for the treatment of inherited and acquired retinal degenerative diseases. These ...